These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 11448921)

  • 1. In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299.
    Ho L; Aytac U; Stephens LC; Ohnuma K; Mills GB; McKee KS; Neumann C; LaPushin R; Cabanillas F; Abbruzzese JL; Morimoto C; Dang NH
    Clin Cancer Res; 2001 Jul; 7(7):2031-40. PubMed ID: 11448921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix.
    Inamoto T; Yamochi T; Ohnuma K; Iwata S; Kina S; Inamoto S; Tachibana M; Katsuoka Y; Dang NH; Morimoto C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3470-7. PubMed ID: 16740772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD26 regulates p38 mitogen-activated protein kinase-dependent phosphorylation of integrin beta1, adhesion to extracellular matrix, and tumorigenicity of T-anaplastic large cell lymphoma Karpas 299.
    Sato T; Yamochi T; Yamochi T; Aytac U; Ohnuma K; McKee KS; Morimoto C; Dang NH
    Cancer Res; 2005 Aug; 65(15):6950-6. PubMed ID: 16061680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.
    Wahl AF; Klussman K; Thompson JD; Chen JH; Francisco LV; Risdon G; Chace DF; Siegall CB; Francisco JA
    Cancer Res; 2002 Jul; 62(13):3736-42. PubMed ID: 12097283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of p38 phosphorylation and topoisomerase IIalpha expression in the B-cell lymphoma line Jiyoye by CD26/dipeptidyl peptidase IV is associated with enhanced in vitro and in vivo sensitivity to doxorubicin.
    Yamochi T; Yamochi T; Aytac U; Sato T; Sato K; Ohnuma K; McKee KS; Morimoto C; Dang NH
    Cancer Res; 2005 Mar; 65(5):1973-83. PubMed ID: 15753397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts.
    Tian ZG; Longo DL; Funakoshi S; Asai O; Ferris DK; Widmer M; Murphy WJ
    Cancer Res; 1995 Nov; 55(22):5335-41. PubMed ID: 7585597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors.
    Inamoto T; Yamada T; Ohnuma K; Kina S; Takahashi N; Yamochi T; Inamoto S; Katsuoka Y; Hosono O; Tanaka H; Dang NH; Morimoto C
    Clin Cancer Res; 2007 Jul; 13(14):4191-200. PubMed ID: 17634548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma.
    Cardarelli PM; Moldovan-Loomis MC; Preston B; Black A; Passmore D; Chen TH; Chen S; Liu J; Kuhne MR; Srinivasan M; Assad A; Witte A; Graziano RF; King DJ
    Clin Cancer Res; 2009 May; 15(10):3376-83. PubMed ID: 19401346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R; Carbone R; Reiss M; Lacy J
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
    Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
    Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins.
    Tazzari PL; de Totero D; Bolognesi A; Testoni N; Pileri S; Roncella S; Reato G; Stein H; Gobbi M; Stirpe F
    Haematologica; 1999 Nov; 84(11):988-95. PubMed ID: 10553158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14.
    Francisco JA; Donaldson KL; Chace D; Siegall CB; Wahl AF
    Cancer Res; 2000 Jun; 60(12):3225-31. PubMed ID: 10866315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
    Wang YD; Hu Y; Zhang L; Huang J; Sun CY
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice.
    Carlo-Stella C; Di Nicola M; Turco MC; Cleris L; Lavazza C; Longoni P; Milanesi M; Magni M; Ammirante M; Leone A; Nagy Z; Gioffrè WR; Formelli F; Gianni AM
    Cancer Res; 2006 Feb; 66(3):1799-808. PubMed ID: 16452241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD26: a novel treatment target for T-cell lymphoid malignancies? (Review).
    Sato K; Dang NH
    Int J Oncol; 2003 Mar; 22(3):481-97. PubMed ID: 12579300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical characterization of SGN-70, a humanized antibody directed against CD70.
    McEarchern JA; Smith LM; McDonagh CF; Klussman K; Gordon KA; Morris-Tilden CA; Duniho S; Ryan M; Boursalian TE; Carter PJ; Grewal IS; Law CL
    Clin Cancer Res; 2008 Dec; 14(23):7763-72. PubMed ID: 19047103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of pyridoisoquinoline derivatives F91873 and F91874, novel multikinase inhibitors with activity against the anaplastic lymphoma kinase.
    Kruczynski A; Mayer P; Marchand A; Vispé S; Fournier E; Annereau JP; Brel V; Barret JM; Delsol G; Imbert T; Fahy J; Bailly C
    Anticancer Drugs; 2009 Jun; 20(5):364-72. PubMed ID: 19322071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo antitumor activity of bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) (METVAN [VO(SO4)(Me2-Phen)2]).
    Narla RK; Chen CL; Dong Y; Uckun FM
    Clin Cancer Res; 2001 Jul; 7(7):2124-33. PubMed ID: 11448932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
    Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
    Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
    Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.